Who Is a Good Candidate for GLP-1 Therapy? An ER Doctor's Honest Take
Dr. RP, MD — Board-Certified, Emergency Medicine & Critical Care Medicine — Founder, Analog Precision Medicine
In the community ERs where I've worked across Los Angeles for the past decade, I've watched the GLP-1 revolution unfold from the patient side. People mentioning they started Ozempic and their blood pressure dropped, their A1c improved, they lost thirty pounds. I've also seen the other side — the muscle loss, the persistent nausea, the 28-year-old prescribed semaglutide without any metabolic workup because she wanted to lose ten pounds.
GLP-1 receptor agonists are genuinely remarkable drugs. But remarkable doesn't mean appropriate for everyone.
Who Belongs on These Medications
Obesity or overweight with comorbidities. Adults with BMI over 30, or BMI over 27 with weight-related comorbidities — hypertension, type 2 diabetes, dyslipidemia, sleep apnea, NAFLD.
Type 2 diabetes or significant insulin resistance. Patients not controlled by lifestyle and first-line agents who have documented metabolic need.
Established cardiovascular disease with overweight. The SELECT trial showed semaglutide reduced major cardiovascular events by 20% in this population.[1] This is among the strongest indications.
Genuine physiological plateau. Patients who have sustained lifestyle modification over time and hit a hormonal or metabolic ceiling — not those who haven't yet tried.
Who Doesn't
Cosmetic weight loss without metabolic indication. Wanting to lose vanity weight without an underlying metabolic condition is not a clinical indication for a potent pharmacological agent.
MTC or MEN2 family history. Personal or family history of medullary thyroid carcinoma or MEN2 syndrome carries a boxed warning. Non-negotiable contraindication.
Prior pancreatitis. The theoretical pancreatitis risk is real enough that prior history warrants avoiding the class.
Patients unwilling to pair medication with resistance training. GLP-1-induced weight loss without muscle preservation sacrifices lean mass along with fat. In an aging adult, that's a dangerous trade. 1.0–1.2 g/kg/day of protein and active resistance training are requirements, not suggestions.
The ER Doctor's Edge
Emergency medicine background shapes prescribing differently. I've managed GLP-1-associated biliary complications — cholecystitis from gallstones caused by rapid weight loss. I've managed severe nausea and dehydration from too-fast titration. I've managed hypoglycemia in diabetics who added a GLP-1 without adjusting their insulin. None of these are reasons not to prescribe. They're reasons to prescribe carefully.
“Most patients regain the majority of lost weight within a year of stopping if the underlying metabolic drivers aren't addressed. The medication treats the symptom. The work treats the cause.”
What Is Required First
Before writing a GLP-1 prescription: comprehensive metabolic panel (fasting insulin, HOMA-IR, HbA1c, lipids with ApoB, liver function, thyroid), body composition assessment to establish baseline lean mass, medication reconciliation (GLP-1s delay gastric emptying and affect absorption of oral medications), and a frank conversation about expectations — including the sobering data that most patients regain the majority of lost weight within a year of stopping if the underlying metabolic drivers aren't addressed.[2]
Then: follow-up at every dose escalation and at regular intervals. Active management, not a prescription and a prayer.
The Bottom Line
GLP-1 agonists have legitimate cardiovascular and metabolic indications beyond cosmetic weight loss. They're powerful tools. But they require proper assessment, monitoring, resistance training, nutritional strategy, and a physician who's managing care comprehensively. If that sounds like more work than ordering Ozempic from a website, it is. That's the point.
References
- 1.Lincoff AM, et al. Semaglutide and cardiovascular outcomes in obesity without diabetes. N Engl J Med. 2023;389:2221–2232. (SELECT trial)
- 2.Wilding JPH, et al. Weight regain after semaglutide withdrawal: STEP 1 extension. Diabetes Obes Metab. 2022.
Dr. RP, MD is dual board-certified in Emergency Medicine and Critical Care Medicine and is the founder of Analog Precision Medicine, a precision medicine practice in Southern California. This article is for educational purposes only and does not constitute medical advice or establish a physician-patient relationship.
← Back to Blog